Literature DB >> 22739647

Percutaneous image-guided delivery for the transplantation of mesenchymal stem cells in the setting of degenerated intervertebral discs.

J David Prologo1, Ali Pirasteh, Nathan Tenley, Lewis Yuan, David Corn, David Hart, Zach Love, Hillard M Lazarus, Zhenghong Lee.   

Abstract

PURPOSE: The delivery of mesenchymal stem cells (MSCs) to their site of action has remained a technical hurdle for clinical researchers in the expanding field of stem cell-based therapy. The purpose of this study was to test the feasibility of percutaneous image-guided needle delivery of bone marrow-derived human MSCs (hMSCs) to degenerated intervertebral discs (IVDs) in a preclinical model and to assess the containment of these cells within the IVDs.
MATERIALS AND METHODS: Degeneration was induced in the lumbar IVDs of four 28-35-kg female pigs. Approximately 100,000 iodine-124 2'-fluoro-2'-deoxy-1β-D-arabinofuranosyl-5-iodouracil-labeled hMSCs were delivered under fluoroscopic guidance to one of the affected discs in each of the animals. The remaining levels served as internal controls. The animals were imaged by computed tomography (CT) and positron emission tomography (PET) immediately after delivery and 3 days after the procedure. Fifteen days after transplantation, immunohistochemical staining was performed on harvested discs to confirm the presence of delivered hMSCs.
RESULTS: After refinement of the technique, PET-CT images on the day of cell transplantation showed initial deposition of the delivered radiolabeled MSCs to the IVD. An additional PET-CT study obtained 3 days later confirmed persistence and containment of activity in the IVD. Findings of histologic evaluation for the presence of human Alu sequences were positive in the treated discs and negative in the controls.
CONCLUSIONS: Image-guided needle delivery of MSCs for treatment of degenerated IVDs is feasible as demonstrated in this preclinical model. Trials of this minimally invasive technique in humans are warranted.
Copyright © 2012 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22739647     DOI: 10.1016/j.jvir.2012.04.032

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  7 in total

Review 1.  Stem cell therapy for intervertebral disc regeneration: obstacles and solutions.

Authors:  Daisuke Sakai; Gunnar B J Andersson
Journal:  Nat Rev Rheumatol       Date:  2015-02-24       Impact factor: 20.543

Review 2.  Mesenchymal stem cell tracking in the intervertebral disc.

Authors:  Charles Handley; Tony Goldschlager; David Oehme; Peter Ghosh; Graham Jenkin
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

Review 3.  The role of stem cell therapies in degenerative lumbar spine disease: a review.

Authors:  David Oehme; Tony Goldschlager; Jeffrey V Rosenfeld; Peter Ghosh; Graham Jenkin
Journal:  Neurosurg Rev       Date:  2015-03-07       Impact factor: 3.042

Review 4.  Cell therapy for the degenerating intervertebral disc.

Authors:  Wei Tong; Zhouyu Lu; Ling Qin; Robert L Mauck; Harvey E Smith; Lachlan J Smith; Neil R Malhotra; Martin F Heyworth; Franklin Caldera; Motomi Enomoto-Iwamoto; Yejia Zhang
Journal:  Transl Res       Date:  2016-11-28       Impact factor: 7.012

Review 5.  Nondestructive Techniques to Evaluate the Characteristics and Development of Engineered Cartilage.

Authors:  Joseph M Mansour; Zhenghong Lee; Jean F Welter
Journal:  Ann Biomed Eng       Date:  2016-01-27       Impact factor: 3.934

Review 6.  Cell-Based Therapies Used to Treat Lumbar Degenerative Disc Disease: A Systematic Review of Animal Studies and Human Clinical Trials.

Authors:  David Oehme; Tony Goldschlager; Peter Ghosh; Jeffrey V Rosenfeld; Graham Jenkin
Journal:  Stem Cells Int       Date:  2015-05-14       Impact factor: 5.443

7.  Lumbar spine intervertebral disc gene delivery of BMPs induces anterior spine fusion in lewis rats.

Authors:  Matthew E Cunningham; Natalie H Kelly; Bernard A Rawlins; Oheneba Boachie-Adjei; Marjolein C H van der Meulen; Chisa Hidaka
Journal:  Sci Rep       Date:  2022-10-07       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.